Eindhoven-based Chromodynamics raises €2M to eliminate guesswork from drug development: Here’s how

Eindhoven-based Chromodynamics, a deep tech company, announced on Monday, that it has raised €2M in Seed funding from investment fund KIKK Capital.

The Dutch company will use the funds to complete the development of its microscopy product and launch commercially into the biomedical research market.

“It is really exciting to secure the funding needed to realise our vision,” says Wouter Vijvers, founder and CEO of Chromodynamics.

“Over the past years, we have done so much market validation and technology development to prove that we have a winner in our hands. Now, we can enter the next phase. Our solution improves upon the state-of-the-art by an order of magnitude on all important performance metrics (throughput, ease-of-use, level of detail), while dramatically reducing costs for the customer,” adds Vijvers.

Chromodynamics: Microscopy innovator

Founded in 2019, Chromodynamics is on a mission to deliver instruments that eliminate guesswork from drug development and prescription.

The company does this by developing innovative microscopy products based on advanced hyperspectral imaging technology.

Located at the High Tech Campus in Eindhoven, the company is preparing to launch a fully automated microscope platform that can autonomously identify cells in tissue samples.

This technology addresses a significant need in the biomedical research market by streamlining drug development.

Typically, testing new compounds for efficacy and safety is complex and time-consuming, often taking months.

Chromodynamics’ solution reduces this analysis time to under a week, helping to better predict patient responses by accurately mapping tissue interactions.

The Dutch company is working to finish product development for a launch in the translational research market.

The goal is to speed up drug development, especially for cancer immunotherapies. Eventually, the platform will be used as a diagnostic tool for personalised medicine.

“I want to live in a world where treatments are kinder to the patient, but harsher on the disease, and known to work for each unique individual before being administered.”, adds Wouter Vijvers. “With the support of KIKK Capital, we have taken a big step towards the launch of a product that brings us closer to that future. And that is what drives our talented team to great heights.”

The investor

KIKK Capital is a deep tech investor that works with startups to build strong and sustainable businesses.

The company supports driven management teams by providing funding and helping them make the most of growth opportunities.

“From the first meeting with Chromodynamics, we were impressed by the founders and their innovative solution addressing a significant challenge in the biotech industry. As a Deep Tech investor and experienced investor in biotech platform technology, we are well-positioned to support Chromodynamics with our expertise in building successful companies and leveraging our network in the biotech industry,” says Johan Sebregts, Managing Partner at KIKK Capital.